The use of fluoroquinolones in the treatment of community-acquired pneumonia and their cardiotoxic effects
Abstract
Fluoroquinolones (FQ) are widely used in the treatment of community-acquired pneumonia (CAP) in certain cases specified in Russian clinical guidelines. However, FQ are known to have cardiotoxic effects. There have been reports on proarrhythmogenic effect of this drug class, which is more often presented as QT prolongation and may lead to the development of “torsade de pointes” and ventricular fibrillation. Adverse effects of FQ on aortic wall leading to the formation of aneurysm are also reported. Given the above, treatment of CAP in patients with chronic heart failure is challenging. This paper provides a review of clinical pharmacology of FQ, their role in the treatment of CAP, general issues related to cardiotoxicity as well as possible cardiotoxic manifestations of this antibiotic class.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.